Bioliberty develops soft robotic exoskeletons designed to restore mobility for individuals recovering from injuries or living with mobility-limiting conditions. Their technology aims to provide personalized support and assistance, empowering users to regain independence and improve their quality of life.

Biotangents develops pen-side diagnostic devices that utilize novel methods for detecting genetic markers of infectious diseases in livestock. Their technology enables rapid identification of pathogens, such as those causing bovine mastitis and Bovine Viral Diarrhea, addressing the critical need for timely disease management in dairy farming.

CamGene Therapeutics develops RNA‑based medicines that target the molecular causes of sensorineural hearing loss. Using a lipid nanoparticle delivery platform, it transports mRNA, siRNA, antisense oligonucleotides and other RNA modalities to cochlear cells to promote hair‑cell regeneration or protection, aiming to provide a scalable, cost‑effective pharmacologic alternative to hearing devices.

Carcinotech manufactures 3D printed living tumors that accurately replicate human tumor biology, providing researchers with precise models for cancer studies. This technology enhances drug testing efficacy and supports the development of personalized treatment strategies, overcoming the limitations of conventional cancer research methods.

Chemify is a platform that digitizes chemistry and chemical discovery by executing chemical code for drug discovery, synthesis, and materials development. This technology accelerates the synthesis of complex molecules and enables the creation of extensive functional libraries, enhancing reproducibility and efficiency in molecular optimization.

Concinnity Genetics builds AI‑driven, RNA‑based control systems that can be integrated into gene and cell therapies to modulate therapeutic activity on demand. Their platform designs custom regulatory circuits that enable reversible activation, repression, or self‑limiting expression, helping biopharma developers improve safety, dose flexibility, and the therapeutic window of their products.

The startup develops a selective oral Chk1 kinase inhibitor that enhances DNA repair mechanisms in cancer cells. This therapy aims to improve treatment efficacy and patient outcomes in oncology by targeting a critical pathway in cancer progression.

Dxcover is developing a multi-cancer diagnostic platform that utilizes liquid biopsy and an AI engine for the early detection of brain tumors. This technology aims to improve patient survival rates by enabling earlier diagnosis, addressing the critical challenge of late-stage cancer detection.

EnsiliTech utilizes a patented ensilication process to encase thermally unstable biomolecules within a silica network for enhanced stability. This technology eliminates the need for cold-chain logistics for vaccines, antibodies, and diagnostics, preventing spoilage and extending shelf-life across a wide temperature range. The method supports both new and existing biopharmaceutical formulations without relying on lyophilization or harsh processing conditions.

The startup has developed a gene silencing platform that enables the engineering of programmable and adaptive cell therapies, allowing for the creation of iPSC-derived products that respond to specific intra- and extra-cellular signals. This technology enhances the efficacy, safety, and accessibility of cell therapies, addressing the limitations of current therapeutic approaches.

Nami Surgical develops miniaturized ultrasonic surgical scalpels designed to improve upon existing tools used in robot-assisted surgery. Their technology focuses on enhancing precision within surgical procedures. This innovation aims to advance medical device capabilities for better patient outcomes.

Naturbeads manufactures biodegradable cellulose microspheres to replace plastic microbeads used in cosmetics, detergents, and other products, addressing the issue of microplastic pollution that harms marine ecosystems. The company utilizes a sustainable production process that sources materials from certified forestry and agricultural waste, ensuring a circular and environmentally friendly approach.

Neupulse offers a discreet wrist‑worn wearable that delivers rhythmic median‑nerve stimulation to modulate brain networks linked to motor control and relaxation, providing a non‑invasive, drug‑free option for stress, anxiety, and tic disorders. The device is self‑administered via an app that tracks usage and offers guidance, and it is built on decades of neuroscience research with ongoing clinical validation.

Novosound offers senseBP, a handheld, cuffless device that uses a patented flexible ultrasound array to directly measure arterial wall movement and deliver medical‑grade blood pressure readings in real time. The calibration‑free solution provides comfortable, non‑compressive monitoring suitable for clinical and home use, and securely integrates data with electronic health records and telehealth platforms.

Penrhos Bio develops organically inspired compounds that disrupt microbial biofilms, which contribute to persistent infections and equipment fouling across various industries. Their targeted biofilm management technology enhances operational efficiency and lowers maintenance costs by effectively reducing biofilm-related issues.

Wobble Genomics develops advanced computational tools for analyzing complex genomic datasets. The platform provides researchers with high-throughput sequence alignment and variant calling capabilities. This accelerates discovery in areas like personalized medicine and disease mechanism identification.